ASTELLAS-2215-CL-0203
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy
AZ-D9470C00001
Phase I/II
OPEN TO ACCRUAL
A Modular Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients with CD123-Positive Hematological Malignancies
BEIGENE-BGB-11417-103
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
BEIGENE-BGB-11417-105
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
COLUMBIAUNIVERSITY-AAAT8639
Phase I/II
OPEN TO ACCRUAL
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
DISC-0974-102
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2a Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
JNJ-75276617ALE1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
NURIX-NX-5948-301
Phase I
OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
ORYZON-CL04-ORY-1001
Phase I
OPEN TO ACCRUAL
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
SCHRODINGER-SGR-1505-101
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
TENEOBIO-TENEOTWO-TNB486-001
Phase I
OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
UAB-19113-NTX-301
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML